The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Improving prognostication in CMML: the role of iCPSS
Luca Lanino, MD, Dana-Farber Cancer Institute, Boston, MA, discusses advances in prognostic risk stratification for patients with chronic myelomonocytic leukemia (CMML). Dr Lanino highlights the international CMML Prognostic Scoring System (iCPSS), which integrates clinical and molecular features to improve risk prediction and inform treatment decisions, including the optimal timing of allogeneic stem cell transplantation. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
